Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Quadrupole ToF Mass Spectrometer

By Drug Discovery Trends Editor | March 5, 2010

watersWaters Corporation SYNAPT G2 System is a quadrupole time-of-flight mass spectrometer that takes qualitative and quantitative to new heights. the SYNAPT G2 system features new QuanTof and enhanced High Definition MS technologies intended to bring scientists closer to reaching their research goals providing researchers with intuitive operation, application flexibility, and a totally new level of performance for biopharmaceutical, metabolite identification, metabonomics, proteomics, biomarker studies, and food and environmental applications.


The SYNAPT G2 System is capable of outstanding qualitative and quantitative performance for both MS and the elevated data acquisition rates of SYNAPT G2 HDMS analysis. For scientists this means performance in excess of 40,000 FWHM resolution, class-leading sensitivity, a data acquisition rate of 20 spectra/second, exact mass (1 ppm RMS) information and a dynamic range of up to five orders of magnitude. When paired with Waters ACQUITY UltraPerformance LC (UPLC) technology, Waters SYNAPT G2 Mass Spectrometer makes maximum use of the power and speed of UPLC outclassing all other LC/MS and LC/MS/MS systems.


Date: March 1, 2010
Source: Waters Corporation


 


Filed Under: Drug Discovery

 

Related Articles Read More >

The FDA’s AI ambitions depend on better data practices
Researchers working in the clinical laboratory
Outpatient clinics are becoming critical Infrastructure for drug trials
SAS launches clinical trial analytics software built on its Viya cloud native analytics platform
Bayer’s Lynkuet approved by FDA for menopausal hot flashes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE